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Abstract: An investigation was directed towards the antiacetylcholinesterase activity 
of the acid aqueous and methanolic extracts of fi ve cyanobacterial taxa, which 
encompasses an enzymatic inhibition essay and the evaluation of the physiological 
responses of mice to cyanobacterial extracts along with toxicological observations. 
The strains Calothrix sp. CCIBt 3320, Tolypothrix sp. CCIBt 3321, Phormidium cf. 
amoenum CCIBt 3412, Phormidium sp. CCIBt 3265, and Geitlerinema splendidum 
CCIBt 3223 were from the São Paulo Botanical Institute Cyanobacterial Culture 
Collection and all of them showed inhibitory effect on acetylcholinesterase activity 
(in vitro) and caused systemic effects similar to those described for anticholinesterase 
drugs (in vivo). With the exception of G. splendidum and Tolypothrix sp. strains, all 
extracts produced reversible antiacetylcolinesterase effects in mice. Complementary 
histopathological studies were carried out on tissues from animals administered with 
Phormidium sp. and P. cf. amoenum.
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Introduction
 Cyanobacteria are common members of 
microscopic populations of freshwater lakes and reservoirs 
worldwide. They are capable of forming blooms and 
producing potent toxins, which can present serious 
human and animal health problems (Van Apeldoorn et al., 
2007, Pearson et al., 2010). Besides cyanotoxins, these 
organisms have the ability to synthesize considerable 
amounts of structurally distinct compounds that can be 
used as food and feed, fuel, dyes, sunscreen agents, as well 
as therapeutic drugs (Abed et al., 2009).
 In scientifi c literature there is an appreciable 
amount of studies on the potential use of cyanobacterial 
compounds as medication, along with cyanotoxin 
poisoning cases in humans by ingesting contaminated 
water and food or by accidental administration during 
dialysis treatment. Some of these compounds are already 
being employed in anal fi ssures and common fi stula 
treatment, as well as anti-HIV drugs (Botos & Swlodawer, 
2003; Garrido et al., 2007), however, one of the most 
interesting set of activities displayed by cyanobacterial 
metabolites is their inhibitory action on certain enzymes 
(Grainger et al., 1989; Chen et al., 2007; Zelik et al., 
2009). The cyanotoxins microcystins and anatoxin-a(S) 
have anti-phosphatase and anticholinesterase effects, 
respectively (Van Apeldoorn et al., 2007). However, there 
are other antienzymatic activities described for compounds 
synthesized by these organisms (Radau, 2000; Sisay et al., 
2009; Matthew et al., 2010). 
 Compounds bearing antiacetylcholinesterase 
action play a very important role in the search for potential 
drug candidates against Alzheimer disease (AD); this 
neurodegenerative condition is associated with brain 
neurotransmitter defi cits and its symptomatic treatment 
is the restoration of cholinergic function by inhibiting 
acetylcholinesterase (Francis et al., 1999; Trevisan et al., 
2003). 
 Therefore, the effect of an 
antiacetylcholinesterase drug is a long-lasting and 
more effective stimulation of the cholinergic system, 
which results in responses from autonomic effector 
organs, autonomic ganglia, as well as skeletal 
muscles, and from cholinergic receptors in the 
Central Nervous System. According to its molecular 
structure, each antiacetylcholinesterase compound 
Article
Biologically active compounds from cyanobacteria extracts: in vivo and in 
vitro aspects 
Luciana R. Carvalho et al.
Rev. Bras. Farmacogn. Braz. J. Pharmacogn. 23(3): May/Jun. 2013472
has its own chemical characteristics that determine 
its reactivity. As a consequence, the binding between 
the antiacetylcholinesterase compound and the enzyme 
shall be either a short, medium (reversible), or long-term 
(irreversible) association, being considered as potential 
therapeutic drugs only the ones which form reversible 
bonds (Nair et al., 2004).
 There is an ongoing search for new bioactive 
compounds in cyanobacterial extracts from the São Paulo 
Institute of Botany Cyanobacterial Culture Collection 
strains, where some caused similar physiological responses 
in the mouse bioassays, which relate to responses 
demonstrated by antiacetylcholinesterase compounds. 
Such extracts were evaluated for AChE inhibition and 
short-term toxicity to mammals; a first step for further 
studies.
Materials and Methods
The organisms and extract preparation
 Five different cyanobacterial strains were 
studied: Calothrix sp. CCIBt 3320, Tolypothrix sp. 
CCIBt 3321, and Phormidium cf. amoenum CCIBt 3412, 
isolated from soil samples in the Atlantic Rainforest, 
State Park of the Serra do Mar, SP (23o24’ S and 
45o11’06’’ W); Phormidium sp. CCIBt 3265, isolated 
from an alkaline lake from the Pantanal, MS (18o57’42’’ 
and 56o37’26’’); and Geitlerinema splendidum CCIBt 
3223, from Guarapiranga Reservoir waters, SP (23o43’ S 
and 46o32’) (Figure 1). The strains were cultured under 
the following conditions: ASM-1 medium, temperature 
23±1 oC, and continuous irradiance 40-50 Mmol/m-2 s-1 
(Azevedo & Sant’Anna, 2003).
 For each strain, the biomass obtained was freeze-
dried, divided into two halves: one of them subjected to 
ultrasound-assisted extraction (5x, 30 s, 100 W) with 0.1 
M aqueous acetic acid (AAE) and the other, with methanol 
100% (ME). After centrifugation (1,750 x g, 50 min), the 
aqueous supernatants were lyophilized and the methanolic 
ones were dried via speed-vac centrifugation. The dried 
samples were stored in hermetically sealed vials, at -20 oC, 
until analysis (Conserva et al., 2011).
In vitro assay: qualitative evaluation of 
acetylcholinesterase inhibitory activity 
 This in vitro assay was accomplished following 
Rhee et al. (2001) TLC autographic protocol: aliquots of 
100 μg of each dried extract were dissolved and spotted 
on a pre-coated plate (Silica gel 60 F254, 10x 10 cm, layer 
thickness 0.2 mm, E. Merck, Germany). The chromatogram 
was developed with mobile phase CHCl3: MeOH:H2O 
(64:36:8, v/v/v), dried and sprayed with the enzyme 
Figure 1. a. G. splendidum CCIBt 3223; b. Calotrix sp.CCIBt 3320; c. Tolypothrix sp. CCIBt 3321; d. Phormidium sp. CCIBt 3265; 
e. CCIBt 3412 Phormidium cf. amoenum.
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solution (6,66 U mL), thoroughly dried and incubated in 
a humid atmosphere, at 37 oC, for 20 min. Subsequently, 
the plate was sprayed with a 0.25% 1-naphthylacetate in 
ethanol plus 0.25% aqueous Fast Blue B salt solution. 
The spots corresponding to potential acetylcholinesterase 
inhibitors were unambiguously identified as clear zones 
against a purple background. The Electric eel AChE type 
V (Product no C 2888, 1000 U) was purchased from Sigma 
as well all analytical grade reagents. 
 The retention factors (Rf) of the compounds 
that positively reacted against the enzyme were also 
calculated.
In vivo assay: acute toxicity study (i.p.)
 Toxicological assays were performed in 
triplicate on each crude extract by using mice of the same 
sex, which simultaneously allowed the achievement 
of reliable data and the use of a minimum number of 
animals (Rangel et al., 2012). The procedures were 
carried out according to the WHO guidelines (Harada 
et al., 1999) and a single dose of 1,000 mg dried cells/
kg body weight was used, which enabled extracts to 
be ranked as low toxicity, if animal death was caused 
(Lawton et al., 1994). Ethical clearance was obtained 
from the Ethical Committee for Animal Research of 
Butantan Institute - Protocol No. 385/07.
 Male Swiss mice (19-21 g, 50 days) were 
intraperitoneally (i.p.) treated with dried aqueous acetic 
acid or methanolic cyanobacterial extracts dissolved 
in Milli-Q water; the control animals received only the 
vehicle (Milli-Q water), according to WHO protocol. Any 
changes in the skin, fur, eyes and respiratory, autonomic 
and central nervous system, somamotor activity and 
behavior pattern were observed, and signs of tremors, 
convulsions, salivation, diarrhea and lethargy and coma 
were noted as well. The animals were observed for 8 
days following administration because, after an extended 
observation time, notable findings on tissue lesions can be 
observed (Rangel et al., 2012). Surviving animals were 
euthanized with CO2, necropsy findings were recorded and 
tissue samples were taken. 
Results and Discussion
Extract preparation and qualitative evaluation of AChE 
inhibitory activity
 The freeze-dried cyanobacterial biomass and 
the dried extract weights are displayed in Table 1, along 
with the qualitative results of the antiacetylcholinesterase 
bioautographic assay (Figure 2) and the Rf (retention 
factors) of spots corresponding to antiacetylcholinesterase 
compounds.
 All extracts were previously analyzed for the 
presence of microcystins (Conserva et al., 2011).
 In vivo assays: acute toxicity study (i.p.)
 In acute toxicity testing, among the treated 
animals, the ones that received the AAE G. splendidum 
CCIBt 3223 and only one administered with AAE 
Tolypothrix CCIBt 3321 died, while all the others showed 
mild and transient physiological effects, which can be 
associated with the intrinsic side effects induced by anti-
AChE drugs (McGleenon et al., 1999; Xavier et al., 2007; 
2008). 
 The physiological responses, time to death, and 
gross changes seen post-mortem are compiled in Chart 1.
 Similar responses were observed in animals 
treated with extracts of all studied strains, which are also 
very similar to those observed in the mouse studies on 
anti-AChE drugs (McGleenon et al., 1999; Xavier, 2008) 
and such responses are related to muscarinic and nicotinic 
Table 1. Biomass and extract dry weights, qualitative anticholinesterase assay results and Rf of the AntiAChE compounds.
Extract strains Freeze-dried biomasses (g) Dried extracts (g) AntiAChE activity
Rf of antiAChE 
compounds
AAE G. splendidum CCIBt 3223 0.7847 0.3941 + 0.28; 0.66
ME G. splendidum CCIBt 3223 0.6675 0.2308 + 0.26; 0.58
AAE Calotrix sp.CCIBt 3320 0.4937 0.1888 + 0.64
EM Calotrix sp.CCIBt 3320 0.2242 0.1135 + 0.37
AAE Tolypothrix sp. CCIBt 3321 0.4050 0.1868 + 0.62
EM Tolypothrix sp. CCIBt 3321 0.3813 0.1144 + 0.38
AAE Phormidium sp. CCIBt 3265 0.4871 0.1727 + 0.66
EM Phormidium sp.CCIBt 3265 0.6398 0.1875 + 0.45; 0.59; 0.66; 0.73
AAE Phormidium cf. amoenum 
CCIBt 3412
0.5052 0.1485 + 0.66
EM Phormidium cf. amoenum 
CCIBt 3412
0.8941 0.2129 + 0.55; 0.59; 0.58
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Figure 2. AE CCIBt 3223, 3265, 3320 and 3421 TLC qualitative antiacetylcholinesterase assay (a, b, c, d and e); ME CCIBt 3223, 
3265, 3320 and 3421 TLC qualitative antiacetylcholinesterase assay (f, g, h, i, and j). Brackets indicate the anticholinesterase 
compounds.
Chat 1. Physiological responses, observation time or time to death, and macroscopic lesions observed post-mortem.
Strains/extract Physiological responses Observation time Main necropsy findings
AAE- G. splendidum  
CCIBt 3223
Dyspnea, loss of reflexes, and 
prostration
Deaths two hours after extract 
administration
With no apparent macroscopic 
changes 
ME- G. splendidum  
CCIBt 3223
Abdominal contractions, loss of 
reflexes, and agitation
Euthanasia seven days after 
administration
Hemorrhagic lungs 
AAE- Calotrix sp.  
CCIBt 3320 
Piloerection, dyspnea, abdominal 
contractions, eyebrow ptosis, loss 
of reflexes and transitory paralysis 
Euthanasia seven days after 
administration
White spots on the liver; liver 
adhered to the intestines.
ME- Calotrix sp.  
CCIBt 3320 
Loss of reflexes, transitory 
paralysis, intense  abdominal 
contractions, dyspnea and 
eyebrow ptosis
Euthanasia seven days after 
administration
Black spots located between the 
liver lobes (N=1)
AAE- Tolypothrix sp.  
CCIBt 3321 
Transitory paralysis, abdominal 
contractions, piloerection, 
dyspnea, and diarrhea
Death four days after 
administration (N=1); 
euthanasia seven days after 
administration (N=2)
Diminished liver size, fusion 
of lobes and white spots on the 
liver. (N=1)
ME- Tolypothrix sp.  
CCIBt 3321
Agitation, itch, scrotal edema, and 
abdominal contractions.
Euthanasia seven days after 
administration
With no apparent macroscopic 
changes 
AAE- Phormidium sp.  
CCIBt 3265
Dyspnea, abdominal contractions, 
and loss of reflexes.
Euthanasia seven days after 
administration
Hemorrhagic lungs, white spots 
on the liver; abnormalities in 
gallbladder morphology
ME- Phormidium sp.  
CCIBt 3265 
Abdominal contractions, 
piloerection, prostration,  eyebrow 
ptosis transitory paralysis,  and 
dyspnea
Euthanasia seven days after 
administration
Hemorrhagic lungs (N=2), and 
degraded lungs (N=1); green 
spot on the stomach
AAE- Phormidium cf. 
amoenum  
CCIBt 3412 
Prostration, piloerection 
abdominal contractions, and loss 
of reflexes
Euthanasia seven days after 
administration
Hemorrhagic lungs (N=1); 
fusion of liver lobes; increased 
peritoneal thickness, with 
hemorrhagic área (N=1)
ME- Phormidium cf. 
amoenum  
CCIBt 3412 
Muscle spasms, abdominal 
contractions, eyebrow ptosis, 
dyspnea, and loss of reflexes
Euthanasia 7 days after 
administration
Hemorrhagic lungs; diminished 
liver size and presence of 
black spots; bubble on the left 
kidney (N=2); green spot on the 
stomach
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actions as well as on the central nervous system. 
 Among the muscarinic manifestations are 
dyspnea, abdominal cramps and diarrhea; among those 
resulting from overstimulation of the nicotinic receptors 
are muscle cramps, motor weakness, paralysis, tachycardia, 
and piloerection, and among those due to Central Nervous 
System are tremors, ataxia, and walking difficulty. The 
extent, the progression and the persistence of clinical 
observations depend on administration route, bioactive 
compound structure, and exposure magnitude (Andrade 
Filho & Romano, 2001). The compound structure defines 
the bond nature to the enzyme, which can be reversible, 
or irreversible, being the intermediate compound short, 
medium (reversible), or long acting (irreversible), 
respectively. The long acting intermediates are considered 
to be toxic (Nair et al., 2004).
 The clinical signs complete regression ranged 
between two to three hours in three out of five groups 
of mice tested; that is, AAE G. splendidum CCIBt 3223 
caused acute intoxication and only one animal that 
received AAE Tolypothrix sp. CCIBt 3321 died after four 
days from administration.
 The results also showed that the AAE of the 
strain G. splendidum CCIBt 3223 possessed a lethal anti-
AChE activity, most likely by the presence of long acting 
inhibitory substances to the enzyme (Nair et al., 2004), but 
there is insufficient information on the AE Tolypothrix sp. 
effects.
 Anatoxin-a(S), anticholinesterase with potent 
lethal effect, is the only organophosphate produced by 
Cyanobacteria (Van Apeldoorn et al., 2007); meanwhile, 
great part of the compounds considered highly toxic are 
synthetic, such as carbamate Aldicarb (Cazenave et al., 
2005) and of the organophosphate Parathion (Bardin et al., 
1994).
 Our results of the in vitro anti-AChE assay 
and clinical observations indicate that the methanolic 
and aqueous extracts of Calothrix sp. CCIBt 3320, 
Tolypothrix sp. CCIBt 3321, Phormidium sp. CCIBt 3265, 
Phormidium cf. amoenum CCIBt 3412, and G. splendidum 
CCIBt 3223 contain compounds which inhibit the enzyme 
acetylcholinesterase in a transient or reversible way.
 Compounds which act as transient 
anticholinesterase drugs should be evaluated as potential 
therapeutic drugs because the current cholinesterase 
inhibitors prescribed for the treatment of AD are tacrine, 
donepezil, rivastigmine, galantamine, and serine which 
present several adverse side-effects such as hepatotoxicity, 
gastrointestinal disturbance and depression (Yoon et al., 
2008). Due to these limiting factors for their use, new 
anticholinesterase drugs will be well received.
 Aside from allowing a detailed observation 
of the biological responses to active compounds, an 
important outcome of the mouse bioassay is to determine 
the nature and extense of the adverse effects to a single 
dose or an overdose of a toxic or a therapeutic compound 
(Xavier, 2008). In our studies, with the exception of the 
acetic acid extract from G. splendidum CCIBt 3223 and 
Tolypothrix sp. CCIBt 3321, all other extracts are not 
lethal and caused physiological responses associated with 
the pharmacological actions of antiacetylcholinesterase 
compounds.
 Complementary histopathological studies were 
carried out on liver, kidney, and lung tissues of animals 
intoxicated with extracts of Phormidium sp CCIBt 3265 
and P. cf. amoenum CCIBt 3412.
 Previous studies have described and illustrated 
the microscopic lesions caused by CCIBt strain 3223 
(Rangel et al., 2012). The mice lungs were severely 
affected, presenting hemorrhage focuses, edema, alveolar 
collapse, and hyperplasia, due to an increase in the number 
of immune system cells (macrophages). Disorganization 
of the hepatic parenchyma, necrosis, loss of vein 
endothelim, and presence of giant multinuclear cells and 
polymorphonuclear cells in the liver were observed. Finally, 
the kidneys of mice intoxicated with AAE CCIBt 3223 
(G. splendidum) presented alterations in the convoluted 
tubules and necrotic areas (Rangel et al., 2012).
 Histological sections from control animal are 
shown in Figure 3. The main alterations observed in the 
organs of animals tested with AAE CCIBt 3265 were: in 
the lungs, edema, hemorrhage, and alveolar collapse and 
in the liver, areas of necrosis and steatosis (Figure 4).
 In the animals that received ME CCIBt 3265, 
necrosis, steatosis, damage in endothelial cells of central 
lobular veins, enlarged sinusoids, inflammatory infiltrate 
close to bile duct, and giant multinuclear cells were 
observed in the liver; in the lungs, hemorrhage and alveolar 
collapse; and in the kidneys, the interstitial space between 
tubules was greater than normal and there was increase in 
light of convoluted tubules (Figure 5).
 The microscopic lesions provoked by AAE 
CCIBt 3412 were shown in the Figure 6: granulomatous 
foci, hemorrhage, and alveolar collapse were seen in the 
lungs, large amounts of inflammatory infiltration close or 
not to bile duct cells were seen in the liver, and enlarged 
convoluted tubules were seen in the kidneys.
 In the only study concerning 
antiacetylcholinesterase effects on mice, the microscopic 
lesions observed were: in the lungs, hemorrhage, edema 
and congestion; in the liver, vacuolar degeneration and 
in the kidneys, hemorrhage, congestion and tubular 
degeneration (Xavier, 2008). Comparison between the 
findings on AAE and ME CCIBt 3265 microscopic lesions 
showed similarity with the results obtained by Xavier 
(2008). Other histological findings could be attributed to 
unknown substances in the extracts.
 In conclusion, the present study identifies G. 
splendidum CCIBt 3223 as a producer of a toxin, which 
administered as a single dose of 1,000 mg dried cells/kg 
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Figure 3. Histological sections from control animals (HE). A and B: Lung (100x, 200x). C and D: Liver (100x, 200x). E and F: 
Kidney (100x, 200x).
body weight, causes animal death within 2 h and indicates 
ME- Tolypothrix sp. CCIBt 3321 as a candidate for further 
studies for potential anticholinesterase drugs.
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